ATE353224T1 - Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz - Google Patents

Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz

Info

Publication number
ATE353224T1
ATE353224T1 AT99971718T AT99971718T ATE353224T1 AT E353224 T1 ATE353224 T1 AT E353224T1 AT 99971718 T AT99971718 T AT 99971718T AT 99971718 T AT99971718 T AT 99971718T AT E353224 T1 ATE353224 T1 AT E353224T1
Authority
AT
Austria
Prior art keywords
dispensing device
composition
active substance
pharmaceutically active
substance
Prior art date
Application number
AT99971718T
Other languages
English (en)
Inventor
Reinhard Glueck
Ulrich Glueck
Andre Collioud
Original Assignee
Berna Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7886959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353224(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Berna Biotech Ag filed Critical Berna Biotech Ag
Application granted granted Critical
Publication of ATE353224T1 publication Critical patent/ATE353224T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99971718T 1998-11-06 1999-11-08 Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz ATE353224T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19851282A DE19851282A1 (de) 1998-11-06 1998-11-06 Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten

Publications (1)

Publication Number Publication Date
ATE353224T1 true ATE353224T1 (de) 2007-02-15

Family

ID=7886959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971718T ATE353224T1 (de) 1998-11-06 1999-11-08 Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz

Country Status (17)

Country Link
EP (1) EP1126875B1 (de)
JP (1) JP2002529427A (de)
KR (1) KR20010080955A (de)
CN (1) CN1331604A (de)
AT (1) ATE353224T1 (de)
AU (1) AU776669B2 (de)
BR (1) BR9915123A (de)
CA (1) CA2348474C (de)
CZ (1) CZ20011567A3 (de)
DE (2) DE19851282A1 (de)
ES (1) ES2279650T3 (de)
HR (1) HRP20010300A2 (de)
HU (1) HUP0202931A2 (de)
PL (1) PL348202A1 (de)
SK (1) SK6092001A3 (de)
WO (1) WO2000027430A2 (de)
ZA (1) ZA200103607B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
WO2003092738A1 (en) * 2002-04-30 2003-11-13 Dnavec Research Inc. Drug- or gene-carrier composition having lowered hemagglutinin activity
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
EP1891028A1 (de) 2005-05-18 2008-02-27 Forschungsverbund Berlin e.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
HUE028512T2 (en) 2005-10-28 2016-12-28 Id Pharma Co Ltd Gene transfer to airway epithelial stem cell using RNA virus spike protein pseudotyped lentiviral vector
WO2007132790A1 (ja) * 2006-05-12 2007-11-22 National University Corporation Hokkaido University 細菌菌体成分を含む脂質膜を有するリポソーム
MX2009013118A (es) * 2007-06-14 2010-03-04 Crucell Switzerland Ag Vacuna intradermica contra la influenza.
JP2014140588A (ja) * 2013-01-25 2014-08-07 Shinko Chemical Co Ltd 噴霧容器
CA3099430A1 (en) 2018-06-05 2019-12-12 Toko Yakuhin Kogyo Co., Ltd. Hepatitis b vaccine transnasal administration system
FR3119772B1 (fr) 2021-02-15 2024-06-14 Aptar France Sas Tête de distribution pour dispositif de distribution nasale d’un produit fluide ou pulvérulent
FR3164925A1 (fr) * 2024-07-26 2026-01-30 Aptar France Sas Dispositif de distribution nasale

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2434875A (en) * 1945-08-11 1948-01-20 Turnbull Jetting device
FR1257220A (fr) * 1960-02-19 1961-03-31 Dispositif nasal électro-thermique d'inhalation
DE8422872U1 (de) * 1984-08-01 1984-10-25 Anasco GmbH, 6200 Wiesbaden Spender zur intranasalen applikation von fluessigkeiten in form von sprays oder tropfen
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
JP2922935B2 (ja) * 1989-08-11 1999-07-26 東興薬品工業株式会社 粘稠液用鼻孔内噴霧容器の使捨てアダプタ
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
FR2739294B1 (fr) * 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
US5797390A (en) * 1996-03-06 1998-08-25 Mcsoley; Thomas E. Nasal inhaler having a directed spray pattern
FR2764807B1 (fr) * 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent

Also Published As

Publication number Publication date
HUP0202931A2 (hu) 2002-12-28
EP1126875B1 (de) 2007-02-07
ES2279650T3 (es) 2007-08-16
SK6092001A3 (en) 2001-12-03
AU776669B2 (en) 2004-09-16
CA2348474C (en) 2008-01-08
JP2002529427A (ja) 2002-09-10
ZA200103607B (en) 2003-09-30
HRP20010300A2 (en) 2002-06-30
WO2000027430A3 (de) 2000-11-23
AU1161200A (en) 2000-05-29
CA2348474A1 (en) 2000-05-18
BR9915123A (pt) 2001-07-31
CN1331604A (zh) 2002-01-16
DE19851282A1 (de) 2000-05-11
PL348202A1 (en) 2002-05-06
WO2000027430A2 (de) 2000-05-18
DE59914183D1 (de) 2007-03-22
CZ20011567A3 (cs) 2001-08-15
EP1126875A2 (de) 2001-08-29
KR20010080955A (ko) 2001-08-25

Similar Documents

Publication Publication Date Title
TR199800631A2 (xx) Ecza form�lasyonu.
BR9810495A (pt) Composição farmacêutica
NO981638D0 (no) Legemiddel- avgivelsesanordning for to eller flere aktive forbindelser
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BG106030A (en) Pharmaceutical composition
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
FI971776A7 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE60019334D1 (de) Antivirale arznei
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
EE200200075A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kompositsioonid
NO20011217D0 (no) Doseringsform omfattende væskeformulering
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.

Legal Events

Date Code Title Description
RZN Patent revoked